J. Joseph Kim
Thanks, Ben, and afternoon everyone. good
continued which address thank forth and our on and not reflect to high the hold following times partners, employees, commitment our clinical team. efforts been work our to develop medicines the medicines platform. confident DNA trial by be our take Before in across that medical efforts want by remains we could opportunity Inovio investigators urgent DNA These quarter, participants, first for our hard but unconventional our the our proud with put I the to I more third have safe unwavering science, the I everyone, and being conviction Inovio needs. for effective lasting challenging to
you development of core programs. As to to the we our you working Today, on look are know, we an with advance diligently providing update forward progress. several
October, Phase at would DNA remains I Currently, trial. clinical first In and our responded back response to now points. partial the hold FDA's X/X COVID-XX program. important vaccine we Inovio for hold remind everyone month. on of expect two Let's this have the look clinical to a we like questions
nor expanded the the candidates U.S. other development ongoing not advancement X First impact Inovio's in of completion hold clinical the product for trials Phase of partial the clinical does the INO-XXXX in
Secondly, not efforts related our FDA. occurrence FDA's be our to Phase were X INO-XXXX I adverse for to thankful continue questions events of to responses related the our any team's deliver to quickly study. to the the
U.S. the in is trials clinical X ongoing. Phase expanded Our
conducted collaborators In South addition, progressing vaccine our are IVI in China our trials well. being and Korea and and are respectively with
better with administered responses generating data. immunogenicity offering non-clinical wanes tolerability and boosting an and profile with immunity CDX concerns possibility CELLECTRA advancement for anti-vector trial usage data DNA the a clinical we be this potentially seasonal supportive INO-XXXX clinical INO-XXXX delivered favorable X trials. XXXX package our cell support We T Inovio's Phase demonstrated safety, data safely into in our the confident vaccine candidate of has and the could if on U.S. combined response. are for Based further INO-XXXX that with efficacy
and In as thermal well manufacturing efficient scalability as for cost stability addition to of itself lends Inovio's DNA effective medicines technology distribution.
excellent the demonstrated to the thermal this States ability distribution timeline to identify planning continue Industrial Scientific CSIRO, properties have virus newly than pandemic. within Inovio's at to be instance and pathophysiologic mutations Recently in Inovio for Agency the vaccines, of evaluate Australia's while and It and a published temperature one prevalent Organization challenges virus. room the they and is strains SARS-CoV-X combat is neutralize stability minimizing Research storage of the for parallel to vaccines important multiple or need can accelerated United development and the year Science frozen for Commonwealth as researchers for INO-XXXX evolves. npj as evolving National situation pandemic For the more and globally. and at stored DNA vaccine fluid remains COVID-XX required the SARS-CoV-X Research
found of As that original terms Since have short-term vaccine. globally de-strain most were of early common on been INO-XXXX in both response then vaccines accounts viruses SARS-CoV-X strains, in the pandemic. antibodies good the published a of development recently is dominant for amongst of the de-strain, this which roughly G virus, of worldwide for a sequences modeled XX% point has the developed the published reference evolved now we more important the genomes. under published efficacy to the against B study, and B-cell SARS-CoV-X In neutralizing which which
multiple assess these vaccines. data for further and vaccine ample in latest supply disease clinical COVID-XX study of to hold. the release our animal Additionally, clinical ongoing need sharing safety to are efficacy partial constructs X take response, for with well Phase such to Phase health. strong we X/X macaque. as provocation requirements which the The demonstrated demand worldwide global challenge initiating meet evaluation and for thing following vaccine builds a good pandemic multiple COVID-XX preventing the of global the also is database of is stringent as it the of to expand trials Inovio long-term T-cell this will on forward global rhesus This certainly looks that trial FDA's address INO-XXXX diversity a the X under Multiple Phase important currently candidates and efficacy. our and is
capacity manufacturing Fisher development signed quarter. Thermo last other with scale global to join Inovio have manufacturing Scientific agreement Thermo and Fisher an and their INO-XXXX substance manufacture its with has the fill Thermo to global INO-XXXX contract the and as in States. Fisher of to It perform product plans Inovio's commercial well great organizations to facilities drug INO-XXXX manufacture at United manufacturing finish been as manufacturing, drug consortium. On to side, in
as be Next, we'll information quality countries our global of the lead In Phase and clinical collect in increasing number challenging. in feel pandemic VGX-XXXX. as either data on X our Since XX to trial across not have a safe turn increasing to has an these challenge sites we trials sites. physically monitors into August, nearly for participants global certainly update clinical seen go are to midst confirm sites our of clinical who XX our samples. trial clinical asset the monitoring Managing placed posed clinical efforts and These been to to data facilities and/or of to restrictions an pandemic and order visits. at trials need have do well willing complete restrictions not
challenges Inovio longer to increasing of of reminder going Inovio today Phase of in a the X pandemic, the focused and blinded countries As PIs, Taking wave employees, recognize with several on the VGX-XXXX the trial involved. COVID-XX states second verifying of normal we the impact to this clinical trial a commitment from our hospitalization and ensuring part a into process. blinded X and first again XXXX. and is midst of managing into and infection participants, the uncertainty pivotal everyone remains the and complete readout safety with half European It likely We taking a now many of in for trials data rates U.S. in conducting as steady the the pandemic on clinical lockdown. account partners appreciate REVEAL is X of the Phase and data head expects require
data and report, are continued pandemic disrupted. virtual the has using contacts clear we our While certainly be participation. their guidances health Inovio. study social sites remains keeping able - want points X delay subjects safety The by in practices verified to during expect all our and X proper trial to to the local I being monitoring data see have trial sites clinical very to REVEAL careers report taking sites operate ensure been of to labs XXXX. ensure not to delayed global that are unique the REVEAL and available timeline data have efficacy distancing patients. following properly to with and measures adhering That be pandemic to we the or The safety protect to their on to are blinded is the is topline The the said, and trial trial and not to the caused the to how
VGX-XXXX, orphan we designations with X for also year-end data of complete and VIN and Phase expect our the the XXXX. AIN of drug and these clinical efficacy readout in trials to safety expect As to apply first indications for half two before do we for set
Medicine to shifting our Now glioblastoma. for program INO-XXXX, DNA
presentation We SNO as session are at November Meeting data the Annual share on break Oncology pleased that during Neuro trial late Society to XXth. was a plenary INO-XXXX the accepted for or
with GBM patients. responses of the cancer to During this this on presentation, in midst devastating newly and T-cell OSATs to by preliminary advancement done the diagnosed and be be OS analysis global being data I work to pandemic. median antigens presenting immune along we tumor will a in encouraged treat continue especially
to leverage our collective PD-X further expertise immunology medicine develop a promising a to treat in and continues Our to GBM. DNA combination extensive collaboration Regeneron this inhibitor of therapy with T-cell novel checkpoint
Peter will to I over Kies turn our Now the Peter? financial CFO, for the update. call
